Recent Updates
Recently added Catalysts

Chemomab Therapeutics Ltd.

CMMBFDA catalysts, PDUFA dates & pipeline intelligence
$1.64
▲ +0.02 · +1.23%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CMMB financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.9252W HIGH $2.99
Volume
166.11 K
Value Traded
268.87 K
Short % Float
0.07%
Days to Cover
1.0
+21.48%Week
+40.17%1 Month
-21.53%3 Month
-1.2%6 Month
-97.1%5 Year
-99.73%All Time

Cash Data

Unlock CMMB cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
11.88 M
EPS (TTM)
-3.89
P/E Ratio
-
Ent. Value
-20.82 M
Total Shares
7.25 M
Float Shares
6.92 M
Insiders
4.53%
Institutions
6.19%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 topline data readout
nebokitug (anti-CCL24 antibody)
Rheumatoid arthritis (RA)
Phase 2BiologicsImmunology
Unlock every CMMB catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CMMB Catalyst Timeline

Dated clinical, regulatory and corporate events for Chemomab Therapeutics Ltd.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Chemomab Therapeutics Ltd.

156Total events
15Upcoming
29Tier-1 (high impact)
2020 to 2028Coverage

Upcoming catalysts 2

T2Trial Initiation
Subscribe to view catalyst details
nebokitug
T3Corporate Approval
Subscribe to view catalyst details

Event history 50

▲Corporate ApprovalCorporate
SEC declared effective Form S-4 registration statement for Chemomab/Scipher merger
●Quarterly UpdateCorporate
Second quarter 2026 financial results announced
●FDA Filing AcceptedRegulatory Filing
Confidential submission of draft Form S-4 to SEC
◆AcquisitionCorporate
Chemomab and Scipher announce definitive merger agreement
▼Equity OfferingCorporate
Private placement of $30 million from investors
●Quarterly UpdateCorporate
Conference call to discuss merger
◆Runway Guidance UpdateCorporate
Combined company cash runway into H2 2028
◆Runway Guidance UpdateCorporate
Cash runway guidance through Q3 2026
▲Poster PresentationnebokitugPresentation
Presented three abstracts at EASL 2026
primary sclerosing cholangitissource ↗
●Quarterly UpdateCorporate
First quarter 2026 financial results and corporate update
Unlock the full CMMB catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CMMB actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-11-10Nebokitug (first-in-class antibody that inhibits the soluble protein CCL24) Phase 2 data readout Phase 2
Unlock 2 more CMMB historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 92%
Micro Cap
(rank 667 of 725)
Percentile Rank
Showing 2 of 8 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Anti-human CCL24 monoclonal antibody BiologicsCompletedNCT04595825Primary Sclerosing CholangitisPhase 2 COMPLETED 77Jan 10, 2025
CM-101 BiologicsCompletedNCT06037577Nonalcoholic Steatohepatitis (NASH)Phase 1 COMPLETED 8May 5, 2019
Unlock the CMMB pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CMMB program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
nebokitug primary sclerosing cholangitisPhase 22026-02-17positive results from five clinical trialsRead MoreChemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceRead More
Scroll for more · summaries link to the source press release
Unlock every CMMB trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CMMB insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Cohen Neil HarrisDirectorSell -1,000 33,000 held$2.80 08/28/2026
Unlock the full CMMB insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Ikarian Capital, LLC 0 % 61.63 K 51.79 K
Unlock every fund holding CMMB
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CMMB
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CMMB ownership
Insider and institutional ownership, quarter by quarter.

CMMB Short Interest

Shares sold short, counted twice a month.

0.07%
Short % of Float
of tradable shares sold short
5.1K
Shares Sold Short
-63.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
48.3K
Avg Daily Volume
the average used for days to cover
Unlock CMMB short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CMMB option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CMMB option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CMMB options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CMMB ranks across every disease it competes in

Competitive Position is a premium feature
See how CMMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CMMB News

CMMB
Nov 2, 2026
CMMBGeneral

Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective

Chemomab Therapeutics and Scipher Medicine announced that the SEC has declared effective their Registration Statement for a proposed merger. A special meeting for Chemomab shareholders to vote on the merger is set for December 4, 2026. If approved, the merger will create a prominent immunology precision medicine company, with plans for a Phase 2 trial for rheumatoid arthritis in 2027.

Read more →
CMMB
Aug 31, 2026
CMMBConferences/Events

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

Chemomab Therapeutics will present at the H.C. Wainwright 28th Annual Global Investor Conference, with CEO Dr. Adi Mor delivering a prerecorded presentation. The company is advancing its anti-CCL24 antibody, nebokitug, into a Phase 2 trial for rheumatoid arthritis. This follows a merger agreement with Scipher Medicine, expected to close by year-end.

Read more →
CMMB
Aug 19, 2026
CMMBGeneral
▲ +9.4%on this news

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics has announced its second quarter 2026 financial results and provided an update on its proposed merger with Scipher Medicine. The merger aims to advance nebokitug, a novel therapy for rheumatoid arthritis, with a Phase 2 trial expected to start in H1 2027. The combined entity is valued at $150 million and will focus on addressing significant unmet needs in immunology-based diseases.

Read more →
CMMB
Jul 8, 2026
CMMBGeneral
▼ -28.9%on this news· ran to -40% by day 3

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Chemomab Therapeutics and Scipher Medicine have announced a merger to advance nebokitug, an anti-CCL24 antibody, through a Phase 2 trial for rheumatoid arthritis. The merger is supported by a $30 million financing commitment and aims to leverage Scipher's AI platform for patient selection. The combined company will operate under the name Scipher Medicine Corporation and is expected to close in Q4 2026, pending shareholder approvals.

Read more →
CMMB
May 14, 2026
CMMBGeneral

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics reported its Q1 2026 financial results, highlighting advancements in its nebokitug program for primary sclerosing cholangitis (PSC). New clinical data presented at major medical meetings indicates nebokitug's potential as a disease-modifying treatment, particularly for PSC patients with co-existing inflammatory bowel disease (IBD). The company is actively pursuing strategic partnerships and has a solid cash position to support ongoing operations.

Read more →
CMMB
Mar 19, 2026
CMMBFDA Updates

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics (NASDAQ: CMMB) reported its financial results for the year and fourth quarter ending December 31, 2025, highlighting significant progress in its nebokitug program for primary sclerosing cholangitis (PSC). The company successfully navigated an FDA End-of-Phase 2 meeting, establishing a clear pathway toward a potential Phase 3 clinical trial. Key achievements from the year included positive SPRING trial results, several scientific presentations that underscored nebokitug's therapeutic potential, and ongoing discussions with strategic partners to advance the program. These developments may ultimately lead to nebokitug becoming the first approved therapy for PSC and other fibro-inflammatory conditions.

Read more →
CMMB
Feb 17, 2026
CMMBConferences/Events

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Dr. Adi Mor and the senior management team will present and engage in one-on-one investor meetings. The company is known for its innovative therapies targeting fibro-inflammatory diseases, particularly its monoclonal antibody nebokitug, which has shown promising results in clinical trials.

Read more →
CMMB
Dec 2, 2025
CMMBPhases

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab Therapeutics announced the publication of results from its Phase 2 SPRING trial assessing nebokitug in primary sclerosing cholangitis (PSC). The study indicated that nebokitug was safe and well-tolerated for up to 48 weeks, with notable improvements in inflammation and fibrosis biomarkers, especially at the 20 mg/kg dose. These promising results support the initiation of a Phase 3 trial, which aims to further evaluate nebokitug's efficacy in treating PSC, a disease currently without adequate treatment options.

Read more →
CMMB
Nov 24, 2025
CMMBConferences/Events

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) will participate in Oppenheimer's Movers in Rare Disease Summit on December 11, 2025. CEO Adi Mor will present a corporate overview and engage in one-on-one meetings with investors. The company is notably advancing nebokitug, a monoclonal antibody designed to treat fibro-inflammatory diseases, which has shown positive results in clinical trials and received favorable regulatory designations from the FDA and EMA. This summit marks an important opportunity for Chemomab to strengthen investor relations and discuss their innovative therapeutic developments.

Read more →
CMMB
Nov 20, 2025
CMMBPhases
▼ -10%on this newsshared move

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Therapeutics reported a net loss of $1.7 million for the third quarter of 2025. The company holds $10.2 million in cash, which is expected to fund operations through the end of the fourth quarter of 2026. R&D expenses decreased to approximately $1 million from $2.8 million in the prior year period. Management stated that regulatory alignment supports launching a single Phase 3 trial for nebokitug as soon as feasible.

Read more →
CMMB
Nov 6, 2025
CMMBPhases

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Chemomab Therapeutics announced that new clinical data from the Phase 2 SPRING trial of nebokitug will be presented at AASLD The Liver Meeting 2025. The data indicates that nebokitug has shown favorable safety and consistent improvements in key biomarkers in patients with primary sclerosing cholangitis (PSC). The company aims to initiate a Phase 3 trial based on these promising results.

Read more →
CMMB
Aug 21, 2025
CMMBConferences/Events

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Chemomab Therapeutics announced that CEO Dr. Adi Mor will present at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will be available via webcast on September 5, 2025. The company is also hosting one-on-one investor meetings during the conference. Chemomab's lead product, nebokitug, has shown positive results in clinical trials and is preparing for a Phase 3 trial in primary sclerosing cholangitis.

Read more →
CMMB
Aug 14, 2025
CMMBFDA Updates
▼ -6.3%on this news

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Therapeutics reported $9.5 million in cash as of June 30, 2025. The company expects this balance to fund operations through the second quarter of 2026. Chemomab also announced a reverse split of its American Depositary Shares. The new ratio will be one ADS to 80 ordinary shares, effective August 26, 2025.

Read more →
CMMB
Jun 30, 2025
CMMBPhases

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

Chemomab Therapeutics presented positive Phase 2 SPRING trial data for nebokitug in primary sclerosing cholangitis (PSC) at BSG Live'25. The treatment demonstrated a favorable safety profile and significant improvements in biomarkers associated with PSC progression. The findings support the advancement of nebokitug to a Phase 3 trial, aiming to address the unmet need for effective PSC therapies.

Read more →
CMMB
Jun 11, 2025
CMMBPhases
▼ -7.5%on this news

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

Chemomab Therapeutics has received positive feedback from the FDA regarding its Phase 3 development program for nebokitug, a treatment for primary sclerosing cholangitis (PSC). The FDA agreed on the Chemistry, Manufacturing, and Controls (CMC) strategy and allowed non-clinical toxicology studies to proceed concurrently with the clinical trial. This advancement supports Chemomab's efforts to finalize the trial details and engage with strategic partners.

Read more →
CMMB
Jun 3, 2025
CMMBFDA Updates

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

Chemomab Therapeutics has received new patent protections for its drug nebokitug in China and Russia, enhancing its intellectual property portfolio. The drug is positioned to potentially become the first approved treatment for primary sclerosing cholangitis (PSC), following positive results from the Phase 2 SPRING trial. The FDA has also outlined a clear pathway for regulatory approval, which is a significant milestone for the company.

Read more →
CMMB
May 15, 2025
CMMBGeneral
▲ +6.6%on this news

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Therapeutics reported its financial results for Q1 2025 and highlighted significant milestones for its lead candidate, nebokitug. The company achieved a clear regulatory pathway with the FDA for a Phase 3 trial aimed at treating primary sclerosing cholangitis (PSC). Positive data from the SPRING trial showed that nebokitug improved key biomarkers in patients with moderate/advanced PSC. Chemomab's cash position is robust, extending its runway into the second quarter of 2026, and it is exploring partnership options to advance its clinical program.

Read more →
CMMB
May 5, 2025
CMMBPhases
▼ -6.3%on this news

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

Chemomab Therapeutics has presented promising Phase 2 data for its drug nebokitug in treating primary sclerosing cholangitis (PSC) at DDW 2025. The trial demonstrated that nebokitug is well-tolerated and showed significant improvements in various biomarkers related to disease progression over 48 weeks. This encouraging data has prompted the company to advance nebokitug to a Phase 3 study, reflecting its potential as a first-in-class treatment for PSC, a disease with currently no FDA-approved therapies.

Read more →
CMMB
Apr 28, 2025
CMMBPhases

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab Therapeutics has announced promising clinical data for its treatment, nebokitug, at EASL 2025. The analysis from the Phase 2 SPRING trial indicates significant and dose-dependent improvements in various biomarkers associated with primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases. Furthermore, pharmacokinetic data demonstrates effective engagement between nebokitug and its target, CCL24, suggesting a robust clinical potential for the therapy in treating PSC. The data will be presented at the upcoming EASL congress in Amsterdam.

Read more →
CMMB
Apr 21, 2025
CMMBPhases

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Therapeutics announced that it will present clinical data on nebokitug (CM-101) for primary sclerosing cholangitis at major upcoming scientific conferences. The company has reported positive results from previous trials and is preparing for a Phase 3 trial based on its Phase 2 SPRING trial outcomes. Nebokitug has received Orphan Drug and Fast Track designations from regulatory authorities.

Read more →

About Chemomab Therapeutics Ltd.

Tel Aviv, L3 12 employees chemomab.com
HeadquartersKIRYAT ATIDIM, BUILDING 7, TEL AVIV, L3, 6158002
BIOPHARMAWATCH ELITE
Trade the next CMMB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime